By Dr Jamie Fletcher

Journal articles

Nelson CB; Rogers S; Roychoudhury K; Tan YS; Atkinson CJ; Sobinoff AP; Tomlinson CG; Hsu A; Lu R; Dray E; Haber M; Fletcher JI; Cesare AJ; Hegde RS; Pickett HA, 2024, 'The Eyes Absent family members EYA4 and EYA1 promote PLK1 activation and successful mitosis through tyrosine dephosphorylation', Nature Communications, 15, http://dx.doi.org/10.1038/s41467-024-45683-4

Murray JE; Valli E; Milazzo G; Mayoh C; Gifford AJ; Fletcher JI; Xue C; Jayatilleke N; Salehzadeh F; Gamble LD; Rouaen JRC; Carter DR; Forgham H; Sekyere EO; Keating J; Eden G; Allan S; Alfred S; Kusuma FK; Clark A; Webber H; Russell AJ; de Weck A; Kile BT; Santulli M; De Rosa P; Fleuren EDG; Gao W; Wilkinson-White L; Low JKK; Mackay JP; Marshall GM; Hilton DJ; Giorgi FM; Koster J; Perini G; Haber M; Norris MD, 2024, 'The transcriptional co-repressor Runx1t1 is essential for MYCN-driven neuroblastoma tumorigenesis', Nature Communications, 15, http://dx.doi.org/10.1038/s41467-024-49871-0

Azzam N; Fletcher JI; Melong N; Lau L; Dolman EM; Mao J; Tax G; Cadiz R; Tuzi L; Kamili A; Dumevska B; Xie J; Chan JA; Senger DL; Grover SA; Malkin D; Haber M; Berman JN, 2024, 'Abstract B007: High-risk pediatric cancer models in zebrafish, mouse and short-term culture predict individual patient responses to therapy', Cancer Research, 84, pp. B007 - B007, http://dx.doi.org/10.1158/1538-7445.pediatric24-b007

Holliday H; Yang J; Dodson E; Nikolic I; Kamili A; Wheatley M; Deng N; Alexandrou S; Davis TP; Kavallaris M; Caldon CE; McCarroll J; De Preter K; Mestdagh P; Marshall GM; Simpson KJ; Fletcher J; Swarbrick A, 2024, 'Erratum: miR-99b-5p, miR-380-3p, and miR-485-3p are novel chemosensitizing miRNAs in high-risk neuroblastoma (Molecular Therapy (2022) 30(3) (1119–1134), (S1525001622000041), (10.1016/j.ymthe.2022.01.004))', Molecular Therapy, 32, pp. 2031 - 2033, http://dx.doi.org/10.1016/j.ymthe.2024.05.008

Vernooij L; Kamili A; Ober K; van Arkel J; Lankhorst L; Vermeulen E; Al-Khakany H; Tax G; van den Boogaard ML; Fletcher JI; Eising S; Molenaar JJ; Dolman MEM, 2024, 'Preclinical assessment of combined BCL-2 and MCL-1 inhibition in high-risk neuroblastoma', EJC Paediatric Oncology, 3, http://dx.doi.org/10.1016/j.ejcped.2024.100168

Hanssen KM; Fletcher JI; Kamili A, 2024, 'Generation of Orthotopic and Subcutaneous Patient-Derived Xenograft Models from Diverse Clinical Tissue Samples of Pediatric Extracranial Solid Tumors', , 2806, pp. 55 - 74, http://dx.doi.org/10.1007/978-1-0716-3858-3_6

Norris M; Murray J; Valli E; Milazzo G; Mayoh C; Gifford A; Fletcher J; Xue C; Jayatilleke N; Gamble L; De Rosa P; Marshall G; Giorgi F; Koster J; Perini G; Haber M, 2024, '24 (PB012): Runx1t1 is an epigenetic regulator essential for MYCN-driven neuroblastoma tumorigenesis', European Journal of Cancer, 211, pp. 114552 - 114552, http://dx.doi.org/10.1016/j.ejca.2024.114552

Murray J; Pandher R; Xiao L; Somers K; Brand J; Mosmann E; Alfred S; Kusuma F; Kearns A; Park JR; Marshall LV; Gorrini C; Chesler L; Hogarty MD; Pearson ADJ; Burns M; Fletcher JI; Ziegler D; Norris MD; Haber M, 2023, 'Abstract B132: Addition of AMXT1501 (polyamine uptake inhibitor) plus DFMO (polyamine synthesis inhibitor) to standard-of-care chemotherapy/anti-GD2 antibody in the TH-MYCN mouse neuroblastoma model, enhances efficacy compared to addition of DFMO alone', Molecular Cancer Therapeutics, 22, pp. B132 - B132, http://dx.doi.org/10.1158/1535-7163.targ-23-b132

Daniel P; Sun CX; Bradshaw G; Shi H; Loi M; Chew N; Parackal S; Tsui V; Liang Y; Koptyra M; Adjumain S; Sun C; Chong WC; Fernando D; Drinkwater C; Tourchi M; Habarakada D; Carvalho D; Storm PB; Baubet V; Sayles LC; Fernandez E; Zhukova N; Dun MD; Ludlow LE; Day B; Stringer BW; Neeman N; Rubens JA; Raabe EH; Vinci M; Tyrrell V; Fletcher JI; Ekert PG; Dumevska B; Ziegler DS; Tsoli M; Sulaiman NFS; Loh AHP; Low SYY; Sweet-Cordero EA; Monje M; Resnick A; Jones C; Downie P; Williams B; Rosenbluh J; Gough D; Cain JE; Firestein R, 2023, 'SYST-15 GENERATION AND MULTI-DIMENSIONAL PROFILING OF A CHILDHOOD CANCER CELL LINE ATLAS DEFINES NEW THERAPEUTIC OPPORTUNITIES', Neuro-Oncology Advances, 5, pp. iii30 - iii30, http://dx.doi.org/10.1093/noajnl/vdad070.119

Mayoh C; Mao J; Xie J; Tax G; Chow SO; Cadiz R; Pazaky K; Barahona P; Ajuyah P; Trebilcock P; Malquori A; Gunther K; Avila A; Yun DY; Alfred S; Gopalakrishnan A; Kamili A; Wong M; Cowley MJ; Jessop S; Lau LMS; Trahair TN; Ziegler DS; Fletcher JI; Gifford AJ; Tsoli M; Marshall GM; Haber M; Tyrrell V; Failes TW; Arndt GM; Lock RB; Ekert PG; M Dolman ME; Wong-Erasmus M; Ajuyah P, 2023, 'High-Throughput Drug Screening of Primary Tumor Cells Identifies Therapeutic Strategies for Treating Children with High-Risk Cancer', Cancer Research, 83, pp. 2716 - 2732, http://dx.doi.org/10.1158/0008-5472.CAN-22-3702

Sun CX; Daniel P; Bradshaw G; Shi H; Loi M; Chew N; Parackal S; Tsui V; Liang Y; Koptyra M; Adjumain S; Sun C; Chong WC; Fernando D; Drinkwater C; Tourchi M; Habarakada D; Sooraj D; Carvalho D; Storm PB; Baubet V; Sayles LC; Fernandez E; Nguyen T; Pörksen M; Doan A; Crombie DE; Panday M; Zhukova N; Dun MD; Ludlow LE; Day B; Stringer BW; Neeman N; Rubens JA; Raabe EH; Vinci M; Tyrrell V; Fletcher JI; Ekert PG; Dumevska B; Ziegler DS; Tsoli M; Syed Sulaiman NF; Loh AHP; Low SYY; Sweet-Cordero EA; Monje M; Resnick A; Jones C; Downie P; Williams B; Rosenbluh J; Gough D; Cain JE; Firestein R, 2023, 'Generation and multi-dimensional profiling of a childhood cancer cell line atlas defines new therapeutic opportunities', Cancer Cell, 41, pp. 660 - 677.e7, http://dx.doi.org/10.1016/j.ccell.2023.03.007

Hastings JF; Latham SL; Kamili A; Wheatley MS; Han JZR; Wong-Erasmus M; Phimmachanh M; Nobis M; Pantarelli C; Cadell AL; O’Donnell YEI; Leong KH; Lynn S; Geng FS; Cui L; Yan S; Achinger-Kawecka J; Stirzaker C; Norris MD; Haber M; Trahair TN; Speleman F; De Preter K; Cowley MJ; Bogdanovic O; Timpson P; Cox TR; Kolch W; Fletcher JI; Fey D; Croucher DR, 2023, 'Memory of stochastic single-cell apoptotic signaling promotes chemoresistance in neuroblastoma', Science Advances, 9, http://dx.doi.org/10.1126/sciadv.abp8314

Hanssen KM; Wheatley MS; Yu DMT; Conseil G; Norris MD; Haber M; Cole SPC; Fletcher JI, 2022, 'GSH facilitates the binding and inhibitory activity of novel multidrug resistance protein 1 (MRP1) modulators', FEBS Journal, 289, pp. 3854 - 3875, http://dx.doi.org/10.1111/febs.16374

Rosser SPA; Atkinson C; Nath CE; Fletcher JI, 2022, 'Quantification of vincristine and tariquidar by liquid chromatography-tandem mass spectrometry in mouse whole blood using volumetric absorptive microsampling for pharmacokinetic applications', Journal of Separation Science, 45, pp. 2508 - 2519, http://dx.doi.org/10.1002/jssc.202101013

Lau LMS; Mayoh C; Xie J; Barahona P; MacKenzie KL; Wong M; Kamili A; Tsoli M; Failes TW; Kumar A; Mould EVA; Gifford A; Chow SO; Pinese M; Fletcher JI; Arndt GM; Khuong-Quang DA; Wadham C; Batey D; Eden G; Trebilcock P; Joshi S; Alfred S; Gopalakrishnan A; Khan A; Grebert Wade D; Strong PA; Manouvrier E; Morgan LT; Span M; Lim JY; Cadiz R; Ung C; Thomas DM; Tucker KM; Warby M; McCowage GB; Dalla-Pozza L; Byrne JA; Saletta F; Fellowes A; Fox SB; Norris MD; Tyrrell V; Trahair TN; Lock RB; Cowley MJ; Ekert PG; Haber M; Ziegler DS; Marshall GM; Trahair T, 2022, 'In vitro and in vivo drug screens of tumor cells identify novel therapies for high-risk child cancer', EMBO Molecular Medicine, 14, pp. emmm202114608, http://dx.doi.org/10.15252/emmm.202114608

Schilstra CE; Sansom-Daly UM; Schaffer M; Fardell JE; Anazodo AC; McCowage G; Fletcher JI; Marshall GM; Buchhorn-White J; Evtushenko M; Trahair TN; Ellis SJ, 2022, '"we Have All This Knowledge to Give, so Use Us as a Resource": Partnering with Adolescent and Young Adult Cancer Survivors to Determine Consumer-Led Research Priorities', Journal of Adolescent and Young Adult Oncology, 11, pp. 211 - 222, http://dx.doi.org/10.1089/jayao.2021.0052

Holliday H; Yang J; Dodson E; Nikolic I; Kamili A; Wheatley M; Deng N; Alexandrou S; Davis TP; Kavallaris M; Caldon CE; McCarroll J; De Preter K; Mestdagh P; Marshall GM; Simpson KJ; Fletcher J; Swarbrick A, 2022, 'miR-99b-5p, miR-380-3p, and miR-485-3p are novel chemosensitizing miRNAs in high-risk neuroblastoma', Molecular Therapy, 30, pp. 1119 - 1134, http://dx.doi.org/10.1016/j.ymthe.2022.01.004

Seneviratne JA; Carter DR; Mittra R; Gifford A; Kim PY; Luo JS; Mayoh C; Salib A; Rahmanto AS; Murray J; Cheng NC; Nagy Z; Wang Q; Kleynhans A; Tan O; Sutton SK; Xue C; Chung SA; Zhang Y; Sun C; Zhang L; Haber M; Norris MD; Fletcher JI; Liu T; Dilda PJ; Hogg PJ; Cheung BB; Marshall GM, 2022, 'Inhibition of mitochondrial translocase SLC25A5 and histone deacetylation is an effective combination therapy in neuroblastoma', International Journal of Cancer, 152, pp. 1399 - 1413, http://dx.doi.org/10.1002/ijc.34349

Segura MF; Soriano A; Roma J; Piskareva O; Jiménez C; Boloix A; Fletcher JI; Haber M; Gray JC; Cerdá-Alberich L; Martínez de Las Heras B; Cañete A; Gallego S; Moreno L, 2022, 'Methodological advances in the discovery of novel neuroblastoma therapeutics', Expert Opinion on Drug Discovery, 17, pp. 167 - 179, http://dx.doi.org/10.1080/17460441.2022.2002297

Hanssen KM; Haber M; Fletcher JI, 2021, 'Targeting multidrug resistance-associated protein 1 (MRP1)-expressing cancers: Beyond pharmacological inhibition', Drug Resistance Updates, 59, pp. 100795, http://dx.doi.org/10.1016/j.drup.2021.100795

Gifford AJ; Murray J; Fletcher JI; Marshall GM; Norris MD; Haber M, 2021, 'A Primer for Assessing the Pathology in Mouse Models of Neuroblastoma', Current Protocols, 1, pp. e310, http://dx.doi.org/10.1002/cpz1.310

Xiao L; Somers K; Murray J; Pandher R; Karsa M; Ronca E; Bongers A; Terry R; Ehteda A; Gamble LD; Issaeva N; Leonova KI; O’Connor A; Mayoh C; Venkat P; Quek H; Brand J; Kusuma FK; Pettitt JA; Mosmann E; Kearns A; Eden G; Alfred S; Allan S; Zhai L; Kamili A; Gifford AJ; Carter DR; Henderson MJ; Fletcher JI; Marshall G; Johnstone RW; Cesare AJ; Ziegler DS; Gudkov AV; Gurova KV; Norris MD; Haber M, 2021, 'Dual targeting of chromatin stability by the curaxin CBL0137 and histone deacetylase inhibitor panobinostat shows significant preclinical efficacy in neuroblastoma', Clinical Cancer Research, 27, pp. 4338 - 4352, http://dx.doi.org/10.1158/1078-0432.CCR-20-2357

Grohmann C; Walker F; Devlin M; Luo MX; Chüeh AC; Doherty J; Vaillant F; Ho GY; Wakefield MJ; Weeden CE; Kamili A; Murray J; Po’uha ST; Weinstock J; Kane SR; Faux MC; Broekhuizen E; Zheng Y; Shield-Artin K; Kershaw NJ; Tan CW; Witchard HM; Ebert G; Charman SA; Street I; Kavallaris M; Haber M; Fletcher JI; Asselin-Labat ML; Scott CL; Visvader JE; Lindeman GJ; Watson KG; Burgess AW; Lessene G, 2021, 'Preclinical small molecule WEHI-7326 overcomes drug resistance and elicits response in patient-derived xenograft models of human treatment-refractory tumors', Cell Death and Disease, 12, pp. 268, http://dx.doi.org/10.1038/s41419-020-03269-0

Chen J; Nelson C; Wong M; Tee AE; Liu PY; La T; Fletcher JI; Kamili A; Mayoh C; Bartenhagen C; Trahair TN; Xu N; Jayatilleke N; Wong M; Peng H; Atmadibrata B; Cheung BB; Lan Q; Bryan TM; Mestdagh P; Vandesompele J; Combaret V; Boeva V; Wang JY; Janoueix-Lerosey I; Cowley MJ; MacKenzie KL; Dolnikov A; Li J; Polly P; Marshall GM; Reddel RR; Norris MD; Haber M; Fischer M; Zhang XD; Pickett HA; Liu T, 2021, 'Targeted therapy of TERT-rearranged neuroblastoma with BET bromodomain inhibitor and proteasome inhibitor combination therapy', Clinical Cancer Research, 27, pp. 1438 - 1451, http://dx.doi.org/10.1158/1078-0432.CCR-20-3044

Subhash VV; Huang L; Kamili A; Wong M; Chen D; Venn NC; Atkinson C; Mayoh C; Venkat P; Tyrrell V; Marshall GM; Cowley MJ; Ekert PG; Norris MD; Haber M; Henderson MJ; Sutton R; Fletcher JI; Trahair TN; Vijayasubhash V, 2021, 'Whole-genome sequencing facilitates patient-specific quantitative PCR-based minimal residual disease monitoring in acute lymphoblastic leukaemia, neuroblastoma and Ewing sarcoma', British Journal of Cancer, 126, pp. 482 - 491, http://dx.doi.org/10.1038/s41416-021-01538-z

Tee AE; Ciampa OC; Wong M; Fletcher JI; Kamili A; Chen J; Ho N; Sun Y; Carter DR; Cheung BB; Marshall GM; Liu PY; Liu T, 2020, 'Combination therapy with the CDK7 inhibitor and the tyrosine kinase inhibitor exerts synergistic anticancer effects against MYCN-amplified neuroblastoma', International Journal of Cancer, 147, pp. 1928 - 1938, http://dx.doi.org/10.1002/ijc.32936

Fordham AM; Xie J; Gifford AJ; Wadham C; Morgan LT; Mould EVA; Fadia M; Zhai L; Massudi H; Ali ZS; Marshall GM; Lukeis RE; Fletcher JI; MacKenzie KL; Trahair TN, 2020, 'CD30 and ALK combination therapy has high therapeutic potency in RANBP2-ALK-rearranged epithelioid inflammatory myofibroblastic sarcoma', British Journal of Cancer, 123, pp. 1101 - 1113, http://dx.doi.org/10.1038/s41416-020-0996-2

Gao J; Jung MS; Mayoh C; Venkat P; Hannan KM; Fletcher JI; Kamili A; Gifford AJ; Kusnadi EP; Pearson RB; Hannan RD; Haber M; Norris MD; Somers K; Henderson MJ, 2020, 'Suppression of ABCE1-mediated mRNA translation limits N-MYC-driven cancer progression', Cancer Research, 80, pp. 3706 - 3718, http://dx.doi.org/10.1158/0008-5472.CAN-19-3914

Khan A; Valli E; Lam H; Scott DA; Murray J; Hanssen KM; Eden G; Gamble LD; Pandher R; Flemming CL; Allan S; Osterman AL; Haber M; Norris MD; Fletcher JI; Yu DMT, 2020, 'Targeting metabolic activity in high-risk neuroblastoma through Monocarboxylate Transporter 1 (MCT1) inhibition', Oncogene, 39, pp. 3555 - 3570, http://dx.doi.org/10.1038/s41388-020-1235-2

Le Grand M; Kimpton K; Gana CC; Valli E; Fletcher JI; Kavallaris M, 2020, 'Targeting Functional Activity of AKT Has Efficacy against Aggressive Neuroblastoma', ACS Pharmacology and Translational Science, 3, pp. 148 - 160, http://dx.doi.org/10.1021/acsptsci.9b00085

Huynh T; Murray J; Flemming CL; Kamili A; Hofmann U; Cheung L; Roundhill EA; Yu DMT; Webber HT; Schwab M; Henderson MJ; Haber M; Norris MD; Fletcher JI, 2020, 'CCI52 sensitizes tumors to 6-mercaptopurine and inhibits MYCN-amplified tumor growth', Biochemical Pharmacology, 172, pp. 113770, http://dx.doi.org/10.1016/j.bcp.2019.113770

Kamili A; Atkinson C; Trahair TN; Fletcher JI, 2020, 'Mouse models of high-risk neuroblastoma', Cancer and Metastasis Reviews, http://dx.doi.org/10.1007/s10555-020-09855-0

Kamili A; Gifford AJ; Li N; Mayoh C; Chow S-O; Failes TW; Eden GL; Cadiz R; Xie J; Lukeis RE; Norris MD; Haber M; McCowage GB; Arndt GM; Trahair TN; Fletcher JI, 2020, 'Accelerating development of high-risk neuroblastoma patient-derived xenograft models for preclinical testing and personalised therapy', British Journal of Cancer, 122, pp. 680 - 691, http://dx.doi.org/10.1038/s41416-019-0682-4

Koach J; Holien JK; Massudi H; Carter DR; Ciampa OC; Herath M; Lim T; Seneviratne JA; Milazzo G; Murray JE; McCarroll JA; Liu B; Mayoh C; Keenan B; Stevenson BW; Gorman MA; Bell JL; Doughty L; Hüttelmaier S; Oberthuer A; Fischer M; Gifford AJ; Liu T; Zhang X; Zhu S; Gustafson WC; Haber M; Norris MD; Fletcher JI; Perini G; Parker MW; Cheung BB; Marshall GM, 2019, 'Drugging MYCN oncogenic signaling through the MYCN-PA2G4 binding interface', Cancer Research, 79, pp. 5652 - 5667, http://dx.doi.org/10.1158/0008-5472.CAN-19-1112

Gana CC; Hanssen KM; Yu DMT; Flemming CL; Wheatley MS; Conseil G; Cole SPC; Norris MD; Haber M; Fletcher JI, 2019, 'MRP1 modulators synergize with buthionine sulfoximine to exploit collateral sensitivity and selectively kill MRP1-expressing cancer cells', Biochemical Pharmacology, 168, pp. 237 - 248, http://dx.doi.org/10.1016/j.bcp.2019.07.009

Boutros R; Catchpoole D; Collins K; Cross S; Downie P; Drinkwater C; Fletcher J; Gottardo N; Hunter S; Kirby M; Ludlow L; MacNish M; Maybury M; Moore A; Morrin H; Purdy S; Revesz T; Saffery R; Strong R; Trahair T; Wood A; Byrne J, 2019, 'The Australian and New Zealand Children's Haematology/Oncology Group Biobanking Network', Biopreservation and Biobanking, 17, pp. 95 - 97, http://dx.doi.org/10.1089/bio.2019.0013

Gamble LD; Purgato S; Murray J; Xiao L; Yu DMT; Hanssen KM; Giorgi FM; Carter DR; Gifford AJ; Valli E; Milazzo G; Kamili A; Mayoh C; Liu B; Eden G; Sarraf S; Allan S; Giacomo SD; Flemming CL; Russell AJ; Cheung BB; Oberthuer A; London WB; Fischer M; Trahair TN; Fletcher JI; Marshall GM; Ziegler DS; Hogarty MD; Burns MR; Perini G; Norris MD; Haber M, 2019, 'Inhibition of polyamine synthesis and uptake reduces tumor progression and prolongs survival in mouse models of neuroblastoma', Science Translational Medicine, 11, http://dx.doi.org/10.1126/scitranslmed.aau1099

Fletcher JI; Ziegler DS; Trahair TN; Marshall GM; Haber M; Norris MD, 2018, 'Too many targets, not enough patients: Rethinking neuroblastoma clinical trials', Nature Reviews Cancer, 18, pp. 389 - 400, http://dx.doi.org/10.1038/s41568-018-0003-x

Murray J; Valli E; Yu DMT; Truong AM; Gifford AJ; Eden GL; Gamble LD; Hanssen KM; Flemming CL; Tan A; Tivnan A; Allan S; Saletta F; Cheung L; Ruhle M; Schuetz JD; Henderson MJ; Byrne JA; Norris MD; Haber M; Fletcher JI, 2017, 'Suppression of the ATP-binding cassette transporter ABCC4 impairs neuroblastoma tumour growth and sensitises to irinotecan in vivo', European Journal of Cancer, 83, pp. 132 - 141, http://dx.doi.org/10.1016/j.ejca.2017.06.024

Jung MS; Russell AJ; Liu B; George J; Liu PY; Liu T; DeFazio A; Bowtell DDL; Oberthuer A; London WB; Fletcher JI; Haber M; Norris MD; Henderson MJ, 2017, 'A Myc activity signature predicts poor clinical outcomes in Myc-associated cancers', Cancer Research, 77, pp. 971 - 981, http://dx.doi.org/10.1158/0008-5472.CAN-15-2906

O'Brien R; Tran SL; Maritz MF; Liu B; Kong CF; Purgato S; Yang C; Murray J; Russell AJ; Flemming CL; von Jonquieres G; Pickett HA; London WB; Haber M; Gunaratne PH; Norris MD; Perini G; Fletcher JI; MacKenzie KL, 2016, 'MYC-Driven Neuroblastomas Are Addicted to a Telomerase-Independent Function of Dyskerin', Cancer Research, http://dx.doi.org/10.1158/0008-5472.CAN-15-0879

Carter DR; Sutton SK; Pajic M; Murray J; Sekyere EO; Fletcher J; Beckers A; De Preter K; Speleman F; George RE; Haber M; Norris MD; Cheung BB; Marshall GM, 2016, 'Glutathione biosynthesis is upregulated at the initiation of MYCN-driven neuroblastoma tumorigenesis', Molecular Oncology, 10, pp. 866 - 878, http://dx.doi.org/10.1016/j.molonc.2016.02.004

Fletcher JI; Williams RT; Henderson MJ; Norris MD; Haber M, 2016, 'ABC transporters as mediators of drug resistance and contributors to cancer cell biology', Drug Resistance Updates, 26, pp. 1 - 9, http://dx.doi.org/10.1016/j.drup.2016.03.001

Tee AE; Liu B; Song R; Li J; Pasquier E; Cheung BB; Jiang C; Marshall GM; Haber M; Norris MD; Fletcher JI; Dinger ME; Liu T, 2016, 'The long noncoding RNA MALAT1 promotes tumor-driven angiogenesis by up-regulating pro-angiogenic gene expression', Oncotarget, 7, pp. 8663 - 8675, http://dx.doi.org/10.18632/oncotarget.6675

Koach J; Murray JE; McCarroll J; Milazzo G; Perini G; Haber M; Norris MD; Fletcher JI; Cheung BB; Marshall GM, 2016, 'Proffered Paper: Targeting PA2G4, a novel MYCN co-factor, for the treatment of neuroblastoma', European Journal of Cancer, 61, pp. S7 - S7, http://dx.doi.org/10.1016/s0959-8049(16)61016-x

Cheung L; Yu DMT; Neiron Z; Failes TW; Arndt GM; Fletcher JI, 2015, 'Identification of new MRP4 inhibitors from a library of FDA approved drugs using a high-throughput bioluminescence screen', Biochemical Pharmacology, 93, pp. 380 - 388, http://dx.doi.org/10.1016/j.bcp.2014.11.006

Lau DT; Flemming CL; Gherardi S; Perini G; Oberthuer A; Fischer M; Juraeva D; Brors B; Xue C; Norris MD; Marshall GM; Haber M; Fletcher JI; Ashton LJ, 2015, 'MYCN amplification confers enhanced folate dependence and methotrexate sensitivity in neuroblastoma', Oncotarget, 6, pp. 15510 - 15523, http://dx.doi.org/10.18632/oncotarget.3732

Cheung L; Flemming CL; Watt F; Masada N; Yu DMT; Huynh T; Conseil G; Tivnan A; Polinsky A; Gudkov AV; Munoz MA; Vishvanath A; Cooper DMF; Henderson MJ; Cole SPC; Fletcher JI; Haber M; Norris MD, 2014, 'High-throughput screening identifies Ceefourin 1 and Ceefourin 2 as highly selective inhibitors of multidrug resistance protein 4 (MRP4)', Biochemical Pharmacology, 91, pp. 97 - 108, http://dx.doi.org/10.1016/j.bcp.2014.05.023

Byrne FL; Yang L; Phillips PA; Hansford LM; Fletcher JI; Ormandy CJ; McCarroll JA; Kavallaris M, 2014, 'RNAi-mediated stathmin suppression reduces lung metastasis in an orthotopic neuroblastoma mouse model', Oncogene, 33, pp. 882 - 890, http://dx.doi.org/10.1038/onc.2013.11

Fletcher JI; Gherardi S; Murray J; Burkhart C; Russell A; Valli E; Smith J; Oberthuer A; Ashton LJ; London WB; Marshall GM; Norris MD; Perini G; Haber M, 2012, 'N-Myc Regulates Expression of the Detoxifying Enzyme Glutathione Transferase GSTP1, a Marker of Poor Outcome in Neuroblastoma', Cancer Research, 72, pp. 845 - 853, http://dx.doi.org/10.1158/0008-5472.CAN-11-1885

Back to profile page